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Health data autonomously collected by users are presently considered as largely
beneficial for wellness, prevention, disease management, as well as clinical research,
especially when longitudinal, chronic, home-based monitoring is needed. However,
data quality and reliability are the main barriers to overcome, in order to exploit
such potential. To this end, we designed, implemented, and tested a system to
integrate patient-generated personally collected health data into the clinical research
data workflow, using a standards-based architecture that ensures the fulfillment of the
major requirements for digital data in clinical studies. The system was tested in a clinical
investigation for the optimization of deep brain stimulation (DBS) therapy in patients with
Parkinson’s disease that required both the collection of patient-generated data and of
clinical and neurophysiological data. The validation showed that the implemented system
was able to provide a reliable solution for including the patient as direct digital data source,
ensuring reliability, integrity, security, attributability, and auditability of data. These results
suggest that personally collected health data can be used as a reliable data source
in longitudinal clinical research, thus improving holistic patient’s personal assessment
and monitoring.
Keywords: personal health records, personal health systems, personal health monitoring, telehealth, longitudinal
studies
INTRODUCTION
In the digital era, personal mHealth Apps combined with the Internet of Health Things (IoHT)
technologies have the potential to help patients managing medical conditions, monitor lifestyles,
and provide medical advice (1). Clinical research may benefit from such technologies as well:
personally collected data may enable capturing the personal perspectives on new therapies
compliance or tolerability, patient’s conditions or symptoms. These new types of data, directly
collected by patients in their ecologic environment, can be used in clinical trials to provide a more
realistic view on the target of the clinical investigation (2).
Furthermore, collecting data while the patient is at home and monitoring these data remotely
is easier and cheaper for patients compared to the traditional methods that require a constant
examination by a medical specialist. Moreover, the possibility to access and monitor data related
to disease progression improves patient’s awareness and compliance to therapy (3).
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However, the increased access to institutional health data (i.e.,
electronic health records, EHRs), not only for “reading” purposes
but also for uploading personally collected data, could result in
a loss of control over data quality and reliability, if compared
to data acquired by healthcare professionals within the clinical
center. Also, patient’s personal devices cannot be monitored
efficiently and the data stored in them cannot be easily kept safe:
malware on personal devices could affect patient’ sensitive data or
infect the full system; patients could forget to collect some data,
even though scheduled, or could lose them for technical issues.
Finally, whether stored on a web platform/cloud system or
on the personal device, patient’s personal mHealth applications
create health-related data sets that, even though potentially
relevant for the care pathway, are not integrated with the patient’s
health record. These data silos form a scattered “island” view
requiring to retrieve information from different systems in order
to reconstruct the full view on the patient’s health pathway (1).
Taken together, these considerations suggest that, despite the
potential benefits of personally collected health data for clinical
research, their effective use has to be assessed, and solutions or
strategies to allow such integration need to be defined.
Data usable in clinical trials have however specific
characteristics, knows as “ALCOA” (A–Attributable, L–Legible,
C–Contemporaneous, O–Original, A–Accurate) requirements,
which were extensively described on FDA guidance on electronic
data sources in clinical trials (4). These characteristics are
independent from the data source, that can be either an
automated system, or an electronic health record, or any
other system. “Attributable” means that each data/document,
including their modifications or reviews, should be attributed to
an author and to a target. This implies that the data collection
system needs to keep track of the person/system responsible for
the specific information. “Legible” relates to data readability and
understandability, implying that a human-readable and human-
understandable format has to be provided for visualization.
“Contemporaneous” implies that data are synchronously
recorded, and that any change on the recording has to be fully
tracked: time-stamp, reason for modification, and author’s
signature are mandatory to obtain reliable data sets. “Original”
means that data should be preserved in their original form or in
a certified true copy. When considering the mobile environment,
and patient-generated data, the concept of “original” assumes
and even higher importance because the data collection module
needs to accurately record raw data by permanent means at
the time of the activity and protect them from any further
modifications, in order to preserve originality. “Accurate”
regards data thoroughness and honestness for a consistent
and real representation of the patient’s status, conforming to
protocol. For personally-generated data, in which the author is
the patient, the concept of “accuracy” should take into account
also the problem of reliability due to low patient’s health literacy
and to the use of personal medical devices that can be not
correctly synchronized or maintained. Finally, data collection
should follow the clinical investigation protocol, in order to be of
enough quality to be used in a clinical investigation.
In order to verify whether personally-collected health data,
after being integrated in the care pathway according to the
ALCOA requirements, can be used in clinical research, we
designed and implemented a standards-based system that uses
a) a specifically designed web-based platform that represents the
institutional clinical data collection system (5);
b) a workflow engine to manage the clinical trial process;
c) a set of mobile apps and wearable devices for patient’s
personal data collection that exchanges information with the
web-platform using a standards-based document set.
We tested the system in a clinical investigation for the
optimization of deep brain stimulation (DBS) therapy in patients
with Parkinson’s disease that required the collection of both
patient-generated and clinical/neurophysiological data.
MATERIALS AND METHODS
System Architecture
The system integrates information collected by different actors
(Figure 1), namely the Patient, the Doctor, and the Researcher.
The Patient may be supported by a Caregiver. The architecture
has three main components: The Patient System, the Workflow
Manager (WFM), and the WebBioBank (WBB) (5). The system
is fully described in Marceglia et al. (6).
In the general process of clinical research, the Researcher
defines the measures needed to achieve the research objectives
and a data collection process. In the system for data integrated
data collection proposed in Figure 1, the Patient collects personal
data through the Patient System, while the Doctor collects
clinical data through the WBB. The WFM guarantees the
correct execution of the research protocol, by implementing
the data collection process and workflow (e.g., it reminds the
Doctor to assess the patient, or the Patient to switch her/his
wearable device on). Thanks to data integration, not only the
Doctor can monitor patient’s personally collected data, but
also the Researchers can access the system and analyze the
holistic dataset.
In order to ensure data integrity and respect ALCOA
principles, the system provides access only to required and
authenticated individuals and implements an audit log in which
all date entries, changes, and deletions are mapped, time-
stamped, and signed. Before data storing, the data format is
automatically inspected to detect any error in data input or
caused by data diddling attacks and, to prevent possible loss
of data, a backup, and recovery strategy is implemented. Once
stored in the Patient repository, the original raw data can
be easily accessed via data models with read-only permission.
Any automated or manual data manipulation can only use
the raw data as input and save the new information in a
separate file. Figure 2 shows the workflow of data and signals
in the system, from the personal patient’s system to the
WebBioBank archive.
System Components
The Patient System is composed by hardware and software, and
it includes a Wearable Device (WD), a Mobile Device (MD), and
a mHealth app for the Patient and the Caregiver (Figure 1). The
WD, in this specific application, is a wearable accelerometer that
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FIGURE 1 | System Architecture.
FIGURE 2 | Data flow model between the Patient System and the WebBioBank. The raw data is permanently archived only into the WebBioBank system, and all the
post-processed data is created and archived in different copies.
dialogues with the MD. Patient-reported data (Patient Diary) are
collected through the mHealth app and are sent to the WFM via
an external gateway.
The exchange of XML-based CDA-2 structured documents
between the MD and the WFM ensures anonymous
communication (7) and it prevents from the exchange of
identification data through unsecure connections, as well as
the maintenance of these data into unsafe environments. The
CDA-2 template used is a modified version of the Personal
Healthcare Monitoring Report (PHMR) CDA2 template
(CDAR2_IG_PHMRPTS_R1.1_DSTU_2010OCT) which was
changed to fulfill the requirements of the mHealth App/EHR
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data exchange described in Marceglia et al. (7). The modified
template is referred to as mPHMR.
The WFM-Patient System communication is managed
through exposed services (e.g., to manage reminders and
notifications, to send schedules, etc). The WFM is devoted
to protocol definition and management through a graphical
interface allowing to design graphical flowcharts in a workflow
editor. The Doctor associates the Patient to the specific protocol
that is executed in a workflow engine (Mirth Connect health care
integration engine) (8).
From WFM, the information is sent to the WBB, a web-
based platform for clinical data collection integrated with
signal management and processing (5), also for multicenter
clinical studies. WBB ensures data de-identification and access
control. Anonymous data collection is implemented through
the use of unique patients’ IDs (IDBAC) instead of any
other identifying demographic information. Being unique, the
IDBAC ensures attributability of records to patients. WBB is
defined as a “research” EHR (rEHR) (5) because it integrates
the functionalities of traditional EHRs with those of research
support systems.
Validation Case Study
Telemonitoring of patients with DBS implant is useful since
these patients face a fragile stabilization period immediately after
electrode placement. We decided to validate this system on these
patients after 5 days from the electrode placement in a controlled
environment, to keep the risks for patients as low as possible.
The experimental protocol is depicted in Figure 3. This study
was carried out in accordance with the recommendations of
IRCCS Ca’ Granda Ospedale Maggiore Policlinico review board
with written informed consent from all subjects, in accordance
with the Declaration of Helsinki. The protocol was also approved
by and the Italian Ministry of Health. We enrolled 10 PD
patients who underwent surgery for DBS electrode implant
having externalized leads for a week to connect a wearable device
for aDBS testing. Two perioperative sessions lasting from 7 to 8 h
were conducted the day 5 and 6 after surgery while the patient
was doing his/her normal activities. In the first session, the beta
band power was continuously recorded while the patient took
its post-operative daily medication dose. In the second session,
we added aDBS treatment to beta band power monitoring and
daily medication. A neurologist assessed the clinical state and
fluctuations at 5 time points (Figure 3) through the motor
Unified Parkinson’s Disease Rating Scale part III (UPDRSIII)
and the Unified Dyskinesia Rating Scale (UDysRS). During the
entire duration of the experimental session, the patient filled
in a diary (every 30min) and wore a bracelet to assess his/her
bradykinesia state.
Patient Generated Data Acquisition
Patient generated data consist of personal diary, collecting
the patient’s state every 30min with scheduled alerts and
a wrist accelerometer acquired by a commercially available
wearable device.
Data was collected through a mobile device (Android phones:
Motorola X Play and Huawei Nova Young) with a dedicated
app that acquires the wrist accelerometer data (a Pebble Time
smartwatch with a custom app, connected to the mobile device
via Bluetooth) and provides a clinical diary form every 30min
to be filled-in by the patient. The patient has a personal ID and
password to access the app.
The mobile phone app implements an algorithm that
finds Bradykinesia Acceleration Scores (BAS) using the wrist
FIGURE 3 | Eight-hours experimental protocol.
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accelerometric values without specific tests involved, in an
ecologic but controlled environment. The BAS algorithm was
adapted from the patent of Griffiths and Horne (9).
The app was entirely developed by our team using the native
Android Framework connected to the standard Pebble Time
Smartwatch app that provides the raw sensor data by the standard
intent broadcast.
At the end of the session, as a preliminary feedback on system
usability, a clinician asked the patients if the smartwatch was
uncomfortable during the day. If the answer was “Yes” the patient
was asked to explain why.
System Testing
The system Validation test consisted in two use-case tests: the
first one consists in the interaction of a doctor to fill-in a clinical
form on the WBB system, and the second one consists in the
collection of patient-generated data through a wearable. The
methods and results of the two experiments are reported in
Tables 1–4. Tables 1, 3 detail the two primary use case tests of
the two experiments and their expected results are reported in
Tables 2, 4.
RESULTS
System Implementation
The system was fully implemented to be used in the validation
case study. WBB was configured in terms of users, roles,
TABLE 1 | Use Case test for creating a new de-identified clinical form in WBB
made by a doctor.
Use-Case: create a new de-identified clinical form.
Actors: Doctor (D), WebBioBank System (WBB).
Scenario description: A doctor finds a patient by name and date of birth and
then fills a clinical scale form regarding said patient. After the Doctor finalizes
the form, the data is de-authenticated and archived remotely.
Precondition: the doctor must be authenticated and authorized by the
system, with the IDBAC list of the right OU opened.
Workflow steps:
1. D: uploads the local xml to pair IDBACs to the local system patients;
2. WBB: visualize the name, surname, and date of birth from IDBAC found
into the xml;
3. D: selects the right IDBAC
4. WBB: shows the patient page with all the forms and the acquisition data;
5. D: clicks the form to fill;
6. WBB: shows the right blank form;
7. D: fills the form and clicks “save”;
8. WBB: display the “sign” option;
9. D: the doctor click the sign option, finalizing the form;
Extensions:
3a or 6a. D: selects the wrong IDBAC/Form;
WBB: shows the wrong IDBAC/Form;
D: clicks on the “Go Back” button;
WBB: return to step 1 (IDBAC de-identified);
9a. D: the doctor does not sign the document;
WBB: shows the IDBAC list on step 1 and it displays +1
draft in the inbox;
The Doctor finds the patients in the system and fills the clinical scale form.
and forms to support the 8-h research study in the hospital-
based ecologic but controlled environment. WBB fulfills the
requirements for clinical study data collection: patients are de-
identified to ensure security; the clinical forms are developed by
the researcher (usually the principal investigator), filled in and
signed by the author, reviewed by the principal investigator, and
changes/modifications are tracked, time-stamped, and signed
whenever they occur, thus guaranteeing integrity, attributability,
and reliability. The definition of the “inspector” user role allowed
auditability. Figure 4A shows the snapshots of the main rEHR
forms created to collect data from PD patients undergoing
the experiment.
Two web services were developed to support the
communication and integration between the WBB and the
WFM. The first one (wHvpc) is devoted to the integration of user
roles and patients’ IDs: it allows the verification of the privacy
criteria for doctors/researchers who access the WFM to create
or assign the patient’s protocol and, once the doctor accesses
to assign the study protocol, allows the exchange of patient’s
ID and contact information from WBB to WFM. Then, when
the protocol has been assigned and the patient is registered
in WFM, the WFM deletes contact information and keeps
only the patient’s ID. In this way, the synchronization between
the two systems is guaranteed thus allowing attributability
and integrity, and patient’s contact information do not reside
on WFM, thus allowing security and privacy. The second
one (wHcda) is devoted to the exchange of CDA-2 standard
documents between the WFM and the WBB. Once the WFM
receives patient-generated data from the mobile application,
it creates and encrypts the CDA-2 document according to the
mPHMR template, and sends it to the WBB using the wHcda
web service. Data reliability is therefore ensured by the use of
standard documents that are accepted by the WBB platform and
processed as clinical documents.
TABLE 2 | Use case test results for Table 1.
Expected results:
1. Every System response (WBB) must be carried out correctly.
2. No IDBAC with personal information must remain cached in the grid form
except between steps 2 and 3.
a. Every personal detail must be only retained on the local database file,
no browser must retain this information;
b. This data cannot leave the local machine.
3. Signed form cannot be deleted or modified.
4. Saved but not signed forms can be modified.
Results:
1. Every System step was fulfilled, to test this scenario we used
UPDRSIII and UDysRS forms;
2a. the system was tested with Google Chrome (ver. 62.0.3202) and
Internet Explorer 11 as browsers, no information were visualized on
all the other steps except 2,3;
2b. Wireshark (ver. 2.0.3) was used to test the internet/WLAN traffic
during this test, no personal data was exchanged outside the local
machine;
3. it’s not possible to modify or delete the form, also, the “save”
and the “sign” operation are logged with the system timestamp
(server-side);
4. Saved forms can be modified but not deleted without
Administrator’s rights.
Frontiers in Medicine | www.frontiersin.org 5 June 2019 | Volume 6 | Article 125
D’Antrassi et al. Personally Collected Data for Research
TABLE 3 | Use Case test for the patient data acquisition.
Use Case: Caregiver/Patient use the app and smart bracelet to collect data
and a researcher reads the results in WBB.
Actors: Patient/Caregiver (P), Researcher (R), System (WBB), smartphone
app (APP), smart-bracelet (B).
Scenario description: A Patient/Caregiver logs into the app, the patient
wears the bracelet, and starts the data acquisition (with the app “play”
button).
Precondition: the Patient/Caregiver and the Doctor must be registered into
the system.
Workflow:
1. P: Logs into the app with the patient ID and password;
2. APP: shows the “please, wear the bracelet” pop-up and the “play”
button page;
3. P: Wears the bracelets and press the “play” button;
4. APP: starts the timer;
5. B: starts the accelerometric acquisition and sends the data to the app via
Bluetooth;
6. APP: Every 30min shows the diary page;
7. P: compiles the diary and clicks the “completed” button;
8. APP: write the data in the local database;
9. APP: At the end of the timer count the app shows the initial “play” button
page and sends the data to the WBB;
10. B: stops the acquisition and the transmission;
11. WBB: confirms the successful transmission of the data;
12. R: logins in WBB with Doctor ID and password;
13. WBB: shows the IDBAC lists;
14. R: selects the IDBAC of the patient;
15. WBB: shows the patient page with all the forms and the acquisition
data;
16. R: selects the last acquisition data;
17. WBB: starts the download of the acquisition data and the diary data;
Extensions:
2a or 12a: APP or WBB: shows again the login page with an informative
text (“wrong password/id”); return to step 1.
4a. B: the bracelet is not working or the smartphone Bluetooth is
not on; APP: shows an informative popup, stops the timer;
11a. APP: cannot reach the WBB or the connection is not stable,
APP shows a popup and retry to connect every 5min; if
successful continue to 12.
The Patient wears the bracelet and starts the data acquisition, logging into the app.
On the patient side, the WFM provides the functionalities for
patient’s registration and protocol fulfillment. The WFM stores
the patient data into the correct rEHR on the WBB by calling
the wHcda service passing the identification numbers of the user
(uID), the patient (IDBAC), and the custodian (ID OU). The
patient data inside the database are anonymous for all users,
and only the patient’s doctor can re-identify them by means of
a local registry. De-identification is guaranteed also by the WFM
registration process that does not require patient’s demographic
information, but uses the contact information retrieved at the
time of assignment that are then deleted when the patient is
successfully registered. Thanks to the definition of the patient’s
protocol, the WFM is able to send the activity program to the
patient’s mobile app, and to provide remainders and alerts when
a task is due (e.g., when the patient has to fill-in the diary). In
addition, in the caseWFM does not receive the patient-generated
data on time, according to the protocol, it sends new requests, and
then notifies theWBB of the deviation from the protocol, sending
TABLE 4 | Use Case test results for Table 3.
Expected results:
1. Every System response (APP, B, and WBB) must be visualized correctly.
2. Limited data loss during the acquisition process;
3. At least 8 h acquisition session without recharging the smartphone or the
bracelet;
4. Downloaded data by the researcher must be in a known readable format
(comma separated values or xls, Excel format);
Results:
1. Every System step was fulfilled correctly;
2. Some accelerometric data in particular timeframes were missing
due to the distance of the mobile device from the patient caused
by forgetfulness or special conditions (e.g., MRI or other exams).
In normal operating condition, the data throughput is sufficient to
guarantee more than 80 sample/s.
3. Pebble Time and the smartphone (Motorola Moto X Play) fully
charged lasted more than 8 h.
4. The data was downloaded and analyzed: The correlation between
UPDRSIII scores and the BAS is −0.563, (p < 0.0005, Pearson) for
5 sessions regarding 4 different patients.
a specific CDA-2 with the indication of the deviation using the
wHcda web service.
Patient-generated data collection for the case study, including
a patient’s diary to be filled in and a wearable bracelet for
bradykinesia evaluation (Figure 4B), is shown in the sequence
diagrams in Figure 5. The algorithm in the mobile app generates
a BAS value every 4min of data. BAS is lower when the patient
is bradykinetic (Figure 4C). Bracelet data are preprocessed in
the mobile app to retrieve the bradykinesia score (Figure 4C).
The forms for the patient’s diary consists of a multiple-
choice mutually exclusive list that asks the perceived motor
status through 4 different answers: “OFF: Bradykinesia and
rigidity,” “ST: Transition,” “ON: normal mobility,” and “ON:
disabling dyskinesia.”
The diary and the accelerometer data is stored internally in a
SQLite DBMS. When the device is synchronized with the WFM,
a mPHMR document is generated with the all the BAS data
compressed and encoded in MIME format in an observation of
the CDA-2 document (content-type: application/x-compressed,
Content-Transfer-Encoding: BASE64) and all the diary data on
another plain text observation of the same document. If the
mPHMR document is correctly stored and approved by the
WFM, a positive feedback is sent back to the mobile device and
the internal database is erased for security reason. This feedback
and the other remainders are sent through a web-service exposed
by the WFM. The use of standard CDA-2 documents between
the App and the WFM ensures data integrity, attributability, and
safety (in the CDA-2 the author is the patient, identified only by
his/her ID). In addition, the mobile app does not retrieve any
clinical data, but deletes them when the WFM correctly receives
the CDA-2 and validates the data.
System Validation
In our experiment, we enrolled 10 patients, 2 doctors, and 1
researcher (the principal investigator). In addition, a user with
role “inspector” was created to test the audit functionalities.
On WBB, the researcher created 7 forms, one for patient’s
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FIGURE 4 | System implementation for the validation case study. (A) Snapshot of the WBB form for UPDRS III. (B) Patient mobile device and smart bracelet custom
app. (C) Accelerometer exemplary data. (D) Mean UPDRS III scores grouped by patient reported diary state and relative statistical error. ns: not significative. *: p <
0.05, Pearson. Note that the system was implemented in Italian.
disease history, one for DBS surgery details (target position,
electrodes implanted, intraoperative monitoring results), one
for the details of the experimental setting (levodopa equivalent
dose administered to the patient, neurophysiologic parameters
retrieved to set the aDBS device), one for each clinical assessment
including the UPDRSIII and the UDysRS scale, and one for the
visualization of patient-generated data.
All the expected 140 diary recordings were received by
the system. Of them, 117 were filled-in whereas 23 arrived
with null values. The major reason was one poor compliant
patient who lacked compiling the diary several times. There
were no errors in the data transmission. A total of 130 h of
accelerometer data were recorded. The accelerometer data loss
was due to a poor connection between the wearable device and
the mobile app. Despite this, we analyzed 21 paired data points
(UPDRSIII scores and the mean BAS scores in a data frame
of ± 20min centered on the UPDRSIII score time) and there
was a significant correlation (−0.563, p < 0.0005, Pearson); this
value is above the 0.5 correlation threshold estimated with a 0.05
alpha error and a power of 70% for 21 data-points (10). This
correlation suggests that the measures obtained by the wearable
device are reliable for assessment purposes, even though data
are incomplete.
We analyzed the first recording session diaries of the
four patients correlated with the normalized UPDRSIII scores
screened in their relative time frame. A total of 21 paired data
(UPDRSIII scores and Diary entries) were assessed. There were
no “ON with Dyskinesia” state reported by the patients.
Figure 4D shows the means of the normalized UDPRSIII for
all patient’s states and the relative statistical error. There are
significant differences between “OFF state” and both “transition”
and “ON” states (p < 0.05, Wilcoxon). Conversely, there was no
difference between the transition state and ON state.
The diary categorical answers were also sorted in a ranked
order (assigning 4 to the ON Dyskinesia state, 3 to the ON state,
2 to the transition state, and 1 to the OFF state, asleep state were
left out). This score correlated well with the UPDRS III scores
(−0.7416, p < 0.0005, Pearson) and with the accelerometric
indexes (0.6042, p < 0.05, Pearson).
All patients answered “No” to the smart band tolerance
question “was the smartwatch uncomfortable during the day?”,
therefore confirming an overall tolerability of the system. The
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FIGURE 5 | Sequence diagram of Patient-generated data collection. (A) Accelerometric data acquisition. (B) Diary generation.
smartphone App tolerance and usability were not assessed
not to overburden the recovering patients. The final e-diary
data was used to gain a perspective on the compliance. In
total, all the expected 140 diary recordings were received
by the system. Of them, 117 were filled-in whereas 23
arrived with null values. Of these 23, 20 where filled-in by a
single patient.
It is worthy to notice that some of the Caregivers (family
members mostly) aided the patients filling-in the eDiary even
if instructed not to do that, but it was not possible, with our
resources, to monitor this behavior.
DISCUSSION
In this work, we designed, implemented, and tested the
feasibility of a multi-source patient-centered acquisition system
in a real clinical research study. Our primary focus was
to determine:
- The tolerability of the system to the patient;
- The communication and monitoring infrastructure reliability;
- The quality of the data captured;
- The correlation of these data to a golden standard (UPDRSIII).
This approach follows closely the recommendations steps
4a, 4b, 5, 6 of Clinical Trials Transformation Initiative
recommendations (11). In a future study in a truly ecological
homecare environment, we plan to conduct usability testing
with patients’ focus group and a more formal training program.
The system integrates personally collected health data into
the data acquisition process for a clinical trial, using a
standards-based architecture that ensured the fulfillment
of the major requirements (4). Our results suggest that
the implemented system and architecture were able to
provide a reliable solution for including patients as direct
digital data source, ensuring ALCOA requirements for data
generated either by the patient him/herself of by personal
wearable device.
Due to the commercial nature of the personal devices that can
be used with this architecture, the low clinical literacy and the
lack of clinical supervisionmay present serious issues on accuracy
and reliability. To address these issues, we tested multiple and
independent sources (i.e., accelerometric smartband and patient
diary) to monitor the correct gathering of these data and give the
physician a bigger and more reliable picture related to the same
clinical outcome. The accelerometric smartband relies only on
wearing and turning on the bracelet/cellphone. Instead, the diary
requires a direct self-reporting action by the patient. However,
in this feasibility study, we did not test the system usability but
only collected data on patient’s tolerance (of the smart band)
and compliance (through the number of diaries received), not
to overburden patients and caregivers. In general, the system
was well tolerated, and the compliance was high. However, when
fully exploited in the homecare environment, not only a full
usability study will be run, but also the design of the App will
follow a user-oriented approach, thus limiting intolerability and
poor compliance.
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The heterogeneity of data given by the use of multiple personal
sources can also be used to extract useful information within the
interaction of those data, e.g., the patient cognitive status (diaries)
vs. his/her motor status (bracelet), or to further understand the
issues that patients can have with the device. This approach gives
a more patient-centered perspective without overlooking his/her
real motor condition.
However, personally generated data do not usually
come from app specifically developed and not in
controlled environments. These conditions would appear
inconsistent with our validation process and highlight the
following limitations:
1- the mHealth App was developed ad hoc;
2- the validation was performed in a controlled environment;
3- the sample size of patients involved was small.
Regarding the first point, the generalizability across devices and
Apps of our system architecture deserves some discussion:
- We used a commercial smartband but not all devices are up to
the task, and an appropriate selectionmust be previouslymade.
The loss of data during the evaluation stage was mainly caused
by the low available data storage memory in the bracelet, thus
requiring a continuous connection with the mobile phone to
transfer data and free the memory. This study shows how
the capability of a device to collect data autonomously is
critical during the daily living of these fragile patients who
are not used to keep the mobile phone close to them but
tend to wander off outside its range. This capability will
be a major requirement for future implementations of the
proposed architecture.
- We used a mHealth App developed ad hoc. However, there are
no limitations about the Apps linkable to this architecture. The
only requirement is the use of standards for both acquisition
and exchange of information between the device and the EHR
system. This is an essential requirement for make the data
relevant from a clinical point of view. The developed App
was based on the mPHMR standard but also the latest FHIR
standard is fully viable.
- Besides interoperability standards, if a mHealth app performs
patient-specific analysis and provides patient-specific
diagnosis or treatment recommendations, it must follow
a strict quality system regulation indicated in general
guidelines (12).
- It has been proposed that interoperability issues in health
IT can be addressed by using web services (13, 14). Our
architecture, in agreement with this hypothesis, implements
specific web services to ensure interoperability among the
different systems (WebBioBank, Workflow manager, and
mHealth App) and to enable the communication among
patients/caregiver, researchers and doctors by using standards
such as PHMR template compliant with RIM (CDA2)
and dictionaries.
Regarding the controlled environment, we considered that
DBS patients after surgery for electrode implant face a fragile
stabilization period, and we expected poor compliance and
increased risk. For this reason, we decided to make the
first assessment of the mHealth App in a controlled hospital
environment. However, some characteristics of this controlled
environment resembled those of the home environment. In fact,
during the experiment, even though patients were without the
supervision of the experimenters, they were helped by their
families or other informal caregivers in using the system, thus
mimicking the home environment. Caregivers (family members
mostly) aided the patients filling-in the questionnaire even if
instructed not to do that, but it was not possible, with our
resources, to monitor this behavior. The main difference between
the home and the controlled environments was the initial setup:
the experimenters, at the beginning of the day, helped the patients
to setup the system, which is of course not possible in the home
environment. We therefore anticipate that in a full real-world
scenario patients and caregivers will require specific training in
order to use the system correctly. For these reasons, the system
will require, in the next future, a more focused testing procedure
with the patients in their home environment to further verify
usability and robustness in longitudinal studies. Finally, further
studies of larger populations will be needed to confirm these
important finding.
Our results suggest that an integration between patient-
generated data and clinical data for supporting research studies is
possible. This opens the way for using personally collected health
data to improve or facilitate longitudinal research, introducing
holistic patient’s personal assessment and monitoring.
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